Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "LAC"

1654 News Found

Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer
Drug Approval | July 21, 2025

Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer

European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)


Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Clinical Trials | July 19, 2025

Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl

Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use


Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim
Supply Chain | July 18, 2025

Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim

Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes


Plant-based chemistry essential for home and personal care products:  Vishal Sharma, Executive Director & Chief Executive Officer (Chemicals), Godrej Industries
Opinion | July 17, 2025

Plant-based chemistry essential for home and personal care products: Vishal Sharma, Executive Director & Chief Executive Officer (Chemicals), Godrej Industries

Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products


Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant
Clinical Trials | July 17, 2025

Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant

There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated


Waters, BD biosciences unit agree to $17.5 billion merger
News | July 16, 2025

Waters, BD biosciences unit agree to $17.5 billion merger

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026


PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization
News | July 15, 2025

PharmaJet inks MoU with Egypt’s UPA and EVA Pharma to offer needle-free delivery for routine immunization

The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development


Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
News | July 15, 2025

Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy

Capricor’s BLA for Deramiocel received Priority Review in March 2025


AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Clinical Trials | July 14, 2025

AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo


Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill
News | July 14, 2025

Merck to initiate Phase 3 trials for investigational once-monthly HIV prevention pill

In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally